The estimated Net Worth of Denver Lough is at least $1.73 Milion dollars as of 1 February 2021. Denver Lough owns over 11,111 units of PolarityTE Inc stock worth over $1,728,363 and over the last 8 years Denver sold PTE stock worth over $0.
Denver has made over 16 trades of the PolarityTE Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Denver exercised 11,111 units of PTE stock worth $2,667 on 1 February 2021.
The largest trade Denver's ever made was exercising 11,112 units of PolarityTE Inc stock on 4 January 2021 worth over $2,667. On average, Denver trades about 7,067 units every 16 days since 2016. As of 1 February 2021 Denver still owns at least 7,201,511 units of PolarityTE Inc stock.
You can see the complete history of Denver Lough stock trades at the bottom of the page.
Denver's mailing address filed with the SEC is 1960 S 4250 W, Salt Lake City, UT 84104, USA.
Over the last 6 years, insiders at PolarityTE Inc have traded over $998,958 worth of PolarityTE Inc stock and bought 381,180 units worth $1,230,731 . The most active insiders traders include Steve Gorlin, Peter A Cohen a Paul Elliot Mann. On average, PolarityTE Inc executives and independent directors trade stock every 21 days with the average trade being worth of $3,753. The most recent stock trade was executed by Chris Nolet on 12 January 2023, trading 36,497 units of PTE stock currently worth $8,759.
polarityte, inc. (nasdaq: cool) is the owner of a novel regenerative medicine and tissue engineering platform developed and patented by denver lough md, phd. this radical and proprietary technology employs a patients' own cells for the healing of full-thickness functionally-polarized tissues. if clinically successful, the polarityte platform will be able to provide medical professionals with a truly new paradigm in wound healing and reconstructive surgery by utilizing a patient's own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. it is because polarityte uses a natural and biologically sound platform technology, which is readily adaptable to a wide spectrum of organ and tissue systems, that the company and its world-renowned clinical advisory board, are poised to drastically change the field and future of translational regenerative medicine. more info can be found online at www.polarityte.com welcome to the shift™
PolarityTE Inc executives and other stock owners filed with the SEC include: